Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review.
Lucy Y LiuJoyce M C TengSheri L SpuntJenna L StreloBernice Y KwongLisa C ZabaPublished in: Pediatric blood & cancer (2021)
Cutaneous adverse events (cAEs) from targeted antineoplastic agents and immune checkpoint inhibitors are common in children with cancer and may lead to dose reduction or cessation of critical oncologic treatment. Timely diagnosis and proper management of cAEs in pediatric oncology patients is essential to optimize ongoing cancer-directed therapy and improve quality of life. This systematic review of published studies summarizes dermatologic toxicities to targeted anticancer treatments and immune checkpoint inhibitors.
Keyphrases
- systematic review
- papillary thyroid
- cancer therapy
- end stage renal disease
- squamous cell
- meta analyses
- newly diagnosed
- ejection fraction
- chronic kidney disease
- young adults
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- rectal cancer
- patient reported outcomes
- bone marrow
- robot assisted
- cell therapy
- patient reported
- minimally invasive
- replacement therapy